The Microarray &Genomics Resource provides a full range of service in technologies for applied genomics. The importance of the Resource to the CCSG is reflected by a strong track record of utilization, publications and awarded grants and contracts. The Resource has a rich history of expertise and accomplishment in the Human Genome Project that laid the foundation for array technology development and analysis, development and implementation of high-throughput technologies and distribution of the RPCI BAC/PAC resources worldwide. The Microarray &Genomics Resource is composed of three complementary divisions: (1) The Genomics Division contributes to the application of human and mouse BAG clones for downstream functional analysis. It provides the infrastructure for automation through robotics for large-scale projects. Fifteen BAC/PAC genomic libraries and two cDNA libraries are available for screening, clone selection, characterization and distribution within RPCI. (2) The Microarray Division provides custom array design and analysis such as BAC-based array CGH for the human and mouse genomes, and gene expression, commercial platforms for two-color human, mouse and rat gene expression. Copy number studies are also available using Agilent and NimbleGen whole-genome oligonucleotide arrays. Investigators can request microarray services, including RNA/DNA isolation, amplification, Cy3 and Cy5 probe generation, hybridizations, custom-made cDNA, antibody, ligand and genomic arrays, scanning of microarrayed slides, image acquisition, normalization of data and analysis. (3) The Genotyping Division provides high-throughput genotyping of SNPs, SNP discovery and quantitative methylation services utilizing the Sequenom MALDI-TOF mass spectrometry platform. Investigators can request flexible assays designed for focused genotyping studies on large sample sets for as few as ten to as many as several hundred SNPs or genes. Over the project period, 54 CCSG Program members (43 with peer-reviewed funding) from five CCSG programs utilized the Resource. The Strategic Plan is to continue to provide access to state-of-theart technology facilitating large-scale and/or global analyses for applied genomics. The Director works closely with the CCSG leadership and members to guide, educate and support genomic endeavors. With the recruitment of new leadership and faculty in the CSBT, Til and MTET Programs, it is anticipated that CCSG members in all six CCSG programs will utilize this Resource. The Resource is used by five Programs and 46% of users are CCSG members. $121,671 in CCSG support is requested, representing 9% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-34
Application #
8078043
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
34
Fiscal Year
2010
Total Cost
$341,032
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Nesher, Elimelech; Safina, Alfiya; Aljahdali, Ieman et al. (2018) Role of Chromatin Damage and Chromatin Trapping of FACT in Mediating the Anticancer Cytotoxicity of DNA-Binding Small-Molecule Drugs. Cancer Res 78:1431-1443
Verma, Aparajita; Rich, Laurie J; Vincent-Chong, Vui King et al. (2018) Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer. J Oral Pathol Med 47:484-491
Sheffer, Christine E; Miller, Austin; Bickel, Warren K et al. (2018) The treasure of now and an uncertain future: Delay discounting and health behaviors among cancer survivors. Cancer 124:4711-4719
Szender, J Brian; Kaur, Jasmine; Clayback, Katherine et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. Int J Gynecol Cancer 28:26-33
Azad, T; Janse van Rensburg, H J; Lightbody, E D et al. (2018) A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis. Nat Commun 9:1061
Buas, Matthew F; Li, Christopher I; Anderson, Garnet L et al. (2018) Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. Cancer Epidemiol 56:83-89
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Sandlesh, Poorva; Juang, Thierry; Safina, Alfiya et al. (2018) Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. PLoS One 13:e0199785

Showing the most recent 10 out of 1555 publications